Financing ·
OS Therapies Inc. entered into a settlement agreement with Leonite Fund I, LP to resolve disputes regarding a prior…
OSTXOS Therapies Inc
OS Therapies Inc. entered into a settlement agreement with Leonite Fund I, LP to resolve disputes regarding a prior $10 million secured convertible note financing. Under the terms of the settlement, OS Therapies agreed to pay Leonite $1.9 million in cash and issue 500,000 shares of common stock by August 7, 2026. This payment was funded on August 3, 2026, using proceeds from a new $2.2 million bridge convertible promissory note issued to an accredited investor on August 2, 2026. The settlement results in the cancellation of the original Leonite Note and warrants, while the bridge note matures on September 1, 2026, or converts into future equity offerings. OS Therapies Inc. operates in the veterinary pharmaceutical industry, developing treatments for animal health.